PRZOOM - /newswire/ -
Chalfont St Giles, United Kingdom, 2012/06/11 - Research Collaboration With Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) to Improve Understanding of the Causes and Diagnosis of Alzheimer's Disease and Develop More Effective Disease Management Tools (NYSE: GE). NYSE: GE
GE Healthcare today announced a collaboration with Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) involving its investigational PET imaging agent [18F flutemetamol].
Under the CSIRO agreement, GE Healthcare will provide its investigational imaging agent to the Australian governmental agency for use in the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which seeks to discover which biomarkers, cognitive characteristics, and health and lifestyle factors may determine subsequent development of symptomatic Alzheimer’s disease.
“This collaboration is a part of our ongoing effort to understand and help identify Alzheimer’s disease and the effects of beta amyloid in the brain,” said Pascale Witz, CEO of GE Healthcare Medical Diagnostics. “This is one of the most significant and expansive studies on the aging population and we are proud to be a part of it.”
“Beta amyloid plays a fundamental role in the development of Alzheimer’s disease,” said Professor Christopher Rowe, lead investigator for imaging in the AIBL study. “It is critical that we are able to identify subjects with beta amyloid accumulation so that we are able to study its effects on the brain, but specifically its effects on subjects with no or very mild symptoms. GE Healthcare’s involvement in AIBL means that we are able to extend the cohort that gets this type of test.”
GE Healthcare offers a broad portfolio of imaging resources that support accurate visualization of the signs of neurodegenerative diseases via state-of-the-art scanners, including MRI, PET, and CT which deliver clear visualization of the brain. More specifically, our portfolio today includes cyclotrons and chemistry systems to manufacture PET imaging agents; PET and MR scanners to scan patients; and image analysis software to interpret the results. GE Healthcare is also partnering with pharma to identify a biosignature, or a biological indicator, which may help physicians diagnose Alzheimer’s disease prior to the onset of clinical symptoms.
GE Healthcare has also been a key contributor to the Alzheimer’s Disease Neuroimaging Initiative (ADNI) since its inception. GE Healthcare also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD, and the Coalition Against Major Diseases (CAMD).
About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.
For our latest news, please visit newsroom.gehealthcare.com/.